MedTrace Logo

Study Conducted Among Patients With CML

NCT05476562 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3234

Last updated 2022-11-08

No results posted yet for this study

Summary

Retrospective, non-interventional observational cohort study conducted among patients with CML.

Conditions

  • Chronic Myeloid Leukemia

Interventions

OTHER

Tyrosine Kinase Inhibitors (TKIs)

The study included patients with CML who were previously treated with TKIs, who are relapsed/refractory to/intolerant of TKIs on third or later lines of therapy in the US.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-08
Primary Completion
2021-10-15
Completion
2021-10-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05476562 on ClinicalTrials.gov